277 related articles for article (PubMed ID: 22485156)
1. Development of a unique small molecule modulator of CXCR4.
Liang Z; Zhan W; Zhu A; Yoon Y; Lin S; Sasaki M; Klapproth JM; Yang H; Grossniklaus HE; Xu J; Rojas M; Voll RJ; Goodman MM; Arrendale RF; Liu J; Yun CC; Snyder JP; Liotta DC; Shim H
PLoS One; 2012; 7(4):e34038. PubMed ID: 22485156
[TBL] [Abstract][Full Text] [Related]
2. Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.
Zhu A; Zhan W; Liang Z; Yoon Y; Yang H; Grossniklaus HE; Xu J; Rojas M; Lockwood M; Snyder JP; Liotta DC; Shim H
J Med Chem; 2010 Dec; 53(24):8556-68. PubMed ID: 21105715
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis.
Shu HK; Yoon Y; Hong S; Xu K; Gao H; Hao C; Torres-Gonzalez E; Nayra C; Rojas M; Shim H
PLoS One; 2013; 8(11):e79768. PubMed ID: 24244561
[TBL] [Abstract][Full Text] [Related]
4. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
5. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.
Oum YH; Shetty D; Yoon Y; Liang Z; Voll RJ; Goodman MM; Shim H
Bioorg Med Chem; 2020 Jan; 28(2):115240. PubMed ID: 31843463
[TBL] [Abstract][Full Text] [Related]
6. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
7. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Song JS; Chang CC; Wu CH; Dinh TK; Jan JJ; Huang KW; Chou MC; Shiue TY; Yeh KC; Ke YY; Yeh TK; Ta YN; Lee CJ; Huang JK; Sung YC; Shia KS; Chen Y
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753481
[TBL] [Abstract][Full Text] [Related]
8. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
[TBL] [Abstract][Full Text] [Related]
9. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models.
Yoon Y; Liang Z; Zhang X; Choe M; Zhu A; Cho HT; Shin DM; Goodman MM; Chen ZG; Shim H
Cancer Res; 2007 Aug; 67(15):7518-24. PubMed ID: 17671223
[TBL] [Abstract][Full Text] [Related]
10. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.
Ma L; Qiao H; He C; Yang Q; Cheung CH; Kanwar JR; Sun X
Invest New Drugs; 2012 Apr; 30(2):508-17. PubMed ID: 21080209
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 2,5-diamino and 2,5-dianilinomethyl pyridine analogues as potential CXCR4 antagonists.
Virani S; Liang Z; Yoon Y; Shim H; Mooring SR
Bioorg Med Chem Lett; 2019 Jan; 29(2):220-224. PubMed ID: 30514601
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional fused polypeptide inhibits the growth and metastasis of breast cancer.
Liang AL; Qian HL; Zhang TT; Zhou N; Wang HJ; Men XT; Qi W; Zhang PP; Fu M; Liang X; Lin C; Liu YJ
Drug Des Devel Ther; 2015; 9():5671-86. PubMed ID: 26527862
[TBL] [Abstract][Full Text] [Related]
13. Peptide density targets and impedes triple negative breast cancer metastasis.
Liu D; Guo P; McCarthy C; Wang B; Tao Y; Auguste D
Nat Commun; 2018 Jul; 9(1):2612. PubMed ID: 29973594
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.
Liang Z; Wu T; Lou H; Yu X; Taichman RS; Lau SK; Nie S; Umbreit J; Shim H
Cancer Res; 2004 Jun; 64(12):4302-8. PubMed ID: 15205345
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors.
Gaines T; Camp D; Bai R; Liang Z; Yoon Y; Shim H; Mooring SR
Bioorg Med Chem; 2016 Nov; 24(21):5052-5060. PubMed ID: 27576294
[TBL] [Abstract][Full Text] [Related]
16. Krüppel-like factor 8 activates the transcription of C-X-C cytokine receptor type 4 to promote breast cancer cell invasion, transendothelial migration and metastasis.
Mukherjee D; Lu H; Yu L; He C; Lahiri SK; Li T; Zhao J
Oncotarget; 2016 Apr; 7(17):23552-68. PubMed ID: 26993780
[TBL] [Abstract][Full Text] [Related]
17. LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung.
Zhang J; Chen J; Wo D; Yan H; Liu P; Ma E; Li L; Zheng L; Chen D; Yu Z; Liang C; Peng J; Ren DN; Zhu W
Clin Cancer Res; 2019 Aug; 25(15):4832-4845. PubMed ID: 31010839
[TBL] [Abstract][Full Text] [Related]
18. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of stromal CXCR4 impairs development of lung metastases.
D'Alterio C; Barbieri A; Portella L; Palma G; Polimeno M; Riccio A; Ieranò C; Franco R; Scognamiglio G; Bryce J; Luciano A; Rea D; Arra C; Scala S
Cancer Immunol Immunother; 2012 Oct; 61(10):1713-20. PubMed ID: 22399057
[TBL] [Abstract][Full Text] [Related]
20. Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.
Dong L; You S; Zhang Q; Osuka S; Devi NS; Kaluz S; Ferguson JH; Yang H; Chen G; Wang B; Grossniklaus HE; Van Meir EG
Clin Cancer Res; 2019 Apr; 25(7):2206-2218. PubMed ID: 30563937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
